Report on the efficacy of the novel adalimumab biosimilar GP2017 using Biomedcode’s human TNF transgenic arthritis model Tg197

Medium_tg197-mouse-10-weeks-old

Comparative functional and pharmacological characterization of Sandoz proposed biosimilar adalimumab (GP2017): rationale for extrapolation across indications.

Kronthaler U, Fritsch C, Hainzl O, Seidl A, da Silva A. Expert Opin Biol Ther. 2018 Jul 16:1-10. doi: 10.1080/14712598.2018.1495193.

 

Read the article here>

 

 

 

 

Return to News